Surrozen is a small biotech developing novel and complex bispecific antibodies that target activation of the WNT pathway to take advantage of its regenerative potential. Although the WNT pathway has been studied for decades, Surrozen — following a partnership with Lonza — is aiming to develop the first therapeutics that intervene in this pathway, and only in diseased tissue.